Skip to main content
Clinical Trials/NCT06123728
NCT06123728
Recruiting
Not Applicable

The Clinical Application of Magnetocardiography (MCG) as a Non-invasive Diagnostic Tool for Evaluating Myocardial Ischemic Function in Patients With Stable Coronary Artery Disease

Nanhai Hospital, Guangdong Provincial People's Hospital1 site in 1 country291 target enrollmentApril 19, 2023

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Stable Coronary Artery Disease
Sponsor
Nanhai Hospital, Guangdong Provincial People's Hospital
Enrollment
291
Locations
1
Primary Endpoint
Consistency in comparing MCG and CT-FFR
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

The objective of this observational study is to evaluate the diagnostic effectiveness of magnetocardiography (MCG) in patients with stable coronary artery disease (SCAD) and compare it with coronary CTA (CCTA). Additionally, the study aims to determine the most suitable diagnostic index for MCG. The primary question it seeks to address is whether MCG or MCG combined with CCTA can be utilized to guide the clinical application of percutaneous coronary intervention (PCI) for coronary heart disease.

Detailed Description

1. Patients aged≥18 years with stable coronary artery disease (CCTA stenosis 30%-90%) underwent sequential examinations of MCG and CCTA. The results of CCTA were assessed using CT-FFR, and the diagnostic effectiveness of MCG in evaluating myocardial ischemia was analyzed using CT-FFR as the reference standard. Simultaneously, MCG was compared to CCTA to determine the clinical value of MCG in the functional evaluation of myocardial ischemia. 2. Coronary angiography was performed in patients who met the criteria for the procedure, and revascularization was carried out based on the intraoperative situation. Patients who underwent revascularization were followed up for 1 year, with major adverse cardiovascular events (MACE) as the endpoint. The clinical value of MCG in guiding the treatment of patients with SCAD was evaluated by reviewing the proportion of coronary angiography, revascularization, and MACE in the enrolled patients.

Registry
clinicaltrials.gov
Start Date
April 19, 2023
End Date
February 2026
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Sponsor
Nanhai Hospital, Guangdong Provincial People's Hospital
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Age ≥18 years old.
  • Stable coronary artery disease patients with a coronary CTA stenosis degree of 30% to 90%.
  • Sign informed consent.

Exclusion Criteria

  • Patients diagnosed with acute coronary syndrome.
  • Patients diagnosed with hypertrophic cardiomyopathy.
  • Patients diagnosed with dilated cardiomyopathy.
  • Patients with complex arrhythmias, such as frequent atrial premature beats, ventricular premature beats, and complete bundle branch block.
  • Patients with a left ventricular ejection fraction less than 50%.
  • Patients with chronic obstructive pulmonary disease, heart failure, kidney failure, or other serious diseases.
  • Pregnant women.
  • Patients with an allergy to contrast agents.
  • The study subjects who have metal grafts that interfere with magnetic cardiogram examination.
  • The study subjects who are unable to cooperate with magnetocardiogram examination and CTA.

Outcomes

Primary Outcomes

Consistency in comparing MCG and CT-FFR

Time Frame: 1 year

Initially, MCG was conducted on each patient to assess the extent of myocardial ischemia using magnetic field distribution, pseudo-current density distribution, magnetic field intensity time spectrum line, and magnetic couple parameters. Simultaneously, the CT-FFR cut-off value of 0.8 was employed as the benchmark for this study. The agreement, sensitivity, specificity, and positive/negative predictive value of cardiac ischemia were compared between MCG and CT-FFR.

Secondary Outcomes

  • Major Adverse Cardiac Events (MACE)(1 year)

Study Sites (1)

Loading locations...

Similar Trials